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1. Introduction
Alzheimer’s disease (AD) is the most common form of
dementia and characterized by pathological results at autopsy 
of the accumulation of amyloid-ß (Aß) protein in senile plaques 
and hyper-phosphorylated tau in neurofibrillary tangles in brain 
(Mukaetova-Ladinska et al., 2015). The levels of two measures, 
cerebrospinal fluid (CSF) amyloid-ß42 (Aß42) and total tau 
(T-tau), have been shown strong promise as predictive 
biomarkers of the progression from mild cognitive impairment 
(MCI, a prodromal stage of AD) to AD (Blennow and Hampel, 
2003; Pan et al., 2015). Typically, the pathogenic relevance in 
AD presents a decrease of CSF Aß42 burden and an increase in 
CSF T-tau levels simultaneously (Li et al., 2015).  
 However, the emerging literatures reported that a group of 
individuals have never shown clinical symptoms of AD in their 
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lifetime but detected out tauopathies and amyloid plaques at 
autopsy (Hohman et al., 2014). In addition, some normal 
cognitive individuals presented low CSF Aß42 burden and some 
individuals with definitive diagnosis of AD showed high levels 
of CSF Aß42 due to their lack of amyloid deposition (Fagan et 
al., 2006). The emergence of this situation posed challenges on 
discriminating individuals with AD from normal cognitive, and 
affected the diagnostic potential of these markers. To address 
this issue, a potential biomarker CSF T-tau/Aß42 ratio 
demonstrated its predictive ability. It can be used to detect and 
measure the AD risk with cognitive decline in non-demented 
older adults, and individuals with higher ratio tend to have 
higher risk to develop AD (Fagan et al., 2007). Moreover, prior 
studies also showed that individuals with family history of AD 
had higher risk for AD than those without a family history. This 
indicates that the underlying genetic factors may play an 
important role in AD (Hohman et al., 2014). 
The existing genome-wide association studies (GWAS) have 
analyzed Single Nucleotide Polymorphism (SNP) data and 
discovered a wide array of underlying genetic causes of AD and 
genetic associations with AD biomarkers as intermediate 
quantitative traits (QTs). For many conditions of complex 
diseases and traits, commonly used single marker analysis can 
identify a number of risk genetic loci, but these identified 
variants typically appear to explain only a modest portion of the 
theoretical estimates of genetic heritability (Goudey et al., 
2013). One possible reason is that the univariate methods used 
in GWAS typically ignore the factor of underlying genetic 
interaction, which may contribute to the development of 
disease and trait variance.   
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Thus, one of several putative explanations for the “missing 
heritability” is that the trait variance can partially be explained 
by the SNP-SNP interaction effects in addition to their main 
effects (Becker et al., 2011). Therefore, genome-wide 
interaction studies (GWIS) have recently gained substantial 
attention (J. Li et al., 2015).  
 In this study, we performed both GWAS and GWIS in the 
Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort. 
We used the AD-associated CSF T-tau/Aß42 ratio as QT, and 
tested single-marker main effects and two-marker interactions 
at the genome-wide level. 
2. Materials and Methods 
Data used in the preparation of this article were obtained 
from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) 
database (adni.loni.usc.edu). The ADNI was launched in 2003 
as a public-private partnership, led by Principal Investigator 
Michael W. Weiner, MD. The primary goal of ADNI has been 
to test whether serial magnetic resonance imaging (MRI), 
positron emission tomography (PET), other biological markers, 
and clinical and neuropsychological assessment can be 
combined to measure the progression of mild cognitive 
impairment (MCI) and early Alzheimer’s disease (AD). 
We applied for and were granted permission to use data from 
the ADNI cohort (http://www.adni-info.org/) to conduct 
genetic association and interaction analyses.  
2.1. Subjects 
Participants are ADNI subjects (N=843) with CSF T-tau and 
Aβ42 measures and quality controlled genotyping data available 
at baseline. The sample included 199 cognitively normal (CN), 
85 significant memory concern (SMC), 239 early mild 
cognitive impairment (EMCI), 207 late mild cognitive 
impairment (LMCI), and 113 AD participants. Table 1 shows 
selected participant characteristics at the baseline, which is the 
time point studied in this work. 
2.2. Quality control of genotyping data 
The genotyping data of the ADNI-1, ADNI-GO and ADNI-2 
cohorts were collected using either the Illumina 2.5M array (a 
byproduct of the ADNI whole genome sequencing sample) or 
the Illumina OmniQuad array (Saykin et al., 2010; Shen et al., 
2010; Shen et al., 2014), and were downloaded from the LONI 
website (http://adni.loni.usc.edu). For the present analyses, we 
included SNPs that were present on both arrays.  
Quality control (QC) was performed using the PLINK 
software (version 1.90) (Purcell et al., 2007). SNPs were 
removed from the analysis if any of the following criteria were 
not satisfied: (1) SNPs on chromosome 1-22; (2) call rate per 
SNP ≥ 95%; (3) minor allele frequency ≥ 5% (1,845,510 SNPs 
were removed based on Criteria 1, 2 and 3); and (4) 
Hardy-Weinberg equilibrium (HWE) test of p ≥ 10-6 using CN 
subjects only (198 SNPs were removed). Participants not 
meeting any of the following criteria were removed from 
further analyses: (1) call rate per participant ≥ 90% (none); (2) 
sex check (1 participant was removed); and (3) identity check 
for related pairs (8 sibling pairs and one triplet were identified 
with PI_HAT ≥ 0.25, 9 participants (one from each pair or 
triplet) were randomly selected and included in this study). 
Population stratification analysis was performed using 
EIGENSTRAT (Price et al., 2006), and confirmed using 
STRUCTURE (Pritchard et al., 2000). It yielded 89 participants 
who did not cluster with the remaining subjects and with the 
CEU HapMap samples who are primarily of European ancestry 
(non-Hispanic Caucasians). These 89 participants were 
excluded from the analysis. Among the remaining 1,079 
subjects, only 843 subjects have both genotyping data and 
phenotypes (T-tau and Aß42) after quality control (QC), and 
thus the other 236 participants were excluded. 
After QC, 843 subjects and 563,980 SNPs remained for the 
subsequent genome-wide association and interaction analyses.  
2.3. CSF T-tau/Aß42 biomarker  
In our study, the CSF levels of T-tau and Aß42 at baseline 
were used. The methods for CSF acquisition and biomarker 
measurement have been reported previously (Hampel et al., 
2010; Jagust et al., 2009; Shaw et al., 2009). For this analyses, 
the Aß42 and T-tau data were log-transformed to better 
approximate normality in distribution (Dickerson et al., 2013), 
and the values greater or smaller than 4 SDs (standard 
deviation) from the mean value of Aß42 and T-tau were 
regarded as extreme outliers and excluded from the analyses. 
Table 1. The demographic and clinical characteristics of 843 ADNI participants at baseline studied in this work. 
  CN (N=199) SMC (N=85) EMCI (N=239) LMCI (N=207) AD (N=113) 
Age (years) 74.4(7.79) 72.0(5.48) 71.4(7.30) 72.4(7.61) 75.2(8.19) 
Women 96(48.2%) 50(58.8%) 102(43.6%) 83(40.1%) 45(39.8%) 
Education (years)  16.21(2.82) 16.00(2.79) 16.16(2.80) 16.38(2.53) 16.40(2.56) 
APOE e4 allele present  47(23.6%) 31(36.5%) 99(41.4%) 112(54.1%) 74(65.5%) 
CDR–SOB 0.04(0.14) 0.08(0.18) 1.27(0.77) 1.65(0.94) 4.53(1.70) 
Mini mental status examination 29.06(1.18) 29.04(1.420) 28.34(1.62) 27.54(1.75) 23.12(2.04) 
Logical memory immediate recall (WMS-R) 14.42(3.00) 14.44(3.34) 11.09(2.68) 7.18(3.06) 4.15(2.70) 
Logical memory delayed recall (WMS-R)  13.34(3.12) 13.29(3.31) 8.97(1.73) 3.94(2.70) 1.52(1.80) 
CSF T-tau (Total tau) 69.76(31.76) 66.95(31.68) 77.66(46.97) 98.22(52.50) 126.26(54.47) 
CSF Aβ42 (amyloid-β42) 198.09(52.87) 201.42(49.43) 184.50(51.41) 162.92(52.80) 136.90(36.25) 
Quantitative Traits (QTs) T-tau/Aβ42 ratio 0.40(0.27) 0.37(0.24) 0.50(0.45) 0.70(0.47) 0.98(0.49) 
Abbreviations: AD, Alzheimer’s disease; ADNI, Alzheimer’s Disease Neuroimaging Initiative; CDR–SOB, clinical dementia rating–sum of boxes; CN, 
cognitive normal; SMC, significant memory concern; EMCI, early mild cognitive impairment; LMCI, late mild cognitive impairment; WMS-R, Wechsler 
Memory Scale-Revised. Data are number (%) or mean (s.d). 
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After QC, 843 valid CSF samples remained.  
2.4. Method of GWAS and GWIS  
GWAS was used to evaluate the SNPs main effects at the 
genome-wide level. Our study performed a genotypic model 
based GWAS using PLINK 1.90 to detect the association 
between SNPs and the T-tau/Aß42 ratio with age, gender and 
clinical diagnosis (five values (1-5) indicating CN, SMC, 
EMCI, LMCI and AD respectively) as covariates. Manhattan 
plots and quantile-quantile (Q-Q) plots were generated using 
Haploview (http://www.broad.mit.edu/mpg/haploview/) and R 
(http://www.r-project.org) respectively.  
For GWIS detecting the SNP-SNP interactions, software tool 
INTERSNP (Herold et al., 2009) was used for two-marker 
analysis. The input files of the tool were PLINK genotype files. 
Firstly, single-marker test was performed for GWAS as 
previously described. The SNPs that met the threshold 
(uncorrected p-value ≤ 0.01) were included in the subsequent 
interaction analysis. Linear regression model was used for an 
additive interaction test (full model including both additive and 
dominance effects plus interaction term versus reduced model 
that does not contain interaction terms) on all possible SNP 
pairs among the previous SNPs selected in first step. We 
detected the epistasis interactions with the T-tau/Aß42 ratio as 
QT while controlling for covariates including the baseline age, 
gender, and clinical diagnosis. There were about 22 million 
unique SNP pairs to be examined, and the Bonferroni corrected 
p-value < 0.05 was used as the statistical significance threshold. 
2.5. Post hoc analysis 
 We performed a hierarchical linear regression among the 
significant interactions, used IBM SPSS 20 to estimate the 
amount of variance (R2) on the T-tau/Aß42 level accounted for 
by these interaction terms. We first included the same set of 
covariates (age, gender, and diagnosis) in the linear model, and 
then included apolipoprotein E (APOE) status, the best-known 
AD risk gene (Akiyama et al., 1993), and two main effects of 
SNPs from the significant pair. Finally, we included the 
SNP-SNP interaction term and computed additional variance 
explained by interaction term. The difference in R2 for the 
significant model was calculated in SPSS as ∆R2 = R2full (full 
model with interaction term) – R2domain (reduced model without 
interaction term).  
3. Results 
3.1. Genome-wide association study results  
 The demographic and clinical characteristics of the 843 
participants at baseline were shown in Table 1. Q-Q plot (Fig. 1) 
shows five evident outliers at the high end of the range, and 
indicates no evidence of spurious inflation. The Manhattan plot 
in Fig. 2 shows the same five outliers with high significance, 
and there are a few other significant hits shown above the red 
line (Bonferroni-corrected threshold p-value = 0.05). 
 In single-marker analyses, 24 SNPs exhibited genome-wide 
significance to the T-tau/Aß42 ratio (Table 2). As expected, the 
most significant loci were identified on chromosome 19, 
including rs4420638 (p=3.50E-27) from the APOC1 region, 
rs769449 (p=6.41E-22) within the APOE region, and 
rs2075650 (p=4.40E-17) and rs157582 (p=2.29E-16) within 
the TOMM40 region. Other SNPs identified in this study are 
shown in Table 2. Table 2 also shows the variances explained 
by each identified SNP after controlling two sets of covariates: 
(1) age, gender, and diagnosis; and (2) age, gender, diagnosis, 
 
Fig. 1.  Quantile–quantile (Q–Q) plot of the observed -log10(p-values) from 
the GWAS of T-tau/Aß42 level versus those expected under the null 
hypothesis. 
Table 2. Identified significant genome-wide association loci with quantitative trait T-tau/Aß42 in this study. 
NO. CHR rs_No. Gene Single-marker p_value 
Corrected 
p-value 
R Square No. CHR rs_No. Gene Single-Marker p_Value 
Corrected 
p-value 
R Square 
Modela Modelb Modela Modelb 
1 19 rs4420638 APOC1 3.50E-27 1.97E-21 0.100 0.001 13 1 rs10127852 LPAR3 2.46E-08 0.0137 0.034 0.023 
2 19 rs769449 APOE 6.41E-22 3.62E-16 0.091 0.0 14 15 rs9806191 DAPK2 2.56E-08 0.0143 0.034 0.023 
3 19 rs2075650 TOMM40 4.40E-17 2.48E-11 0.071 0.0 15 11 rs7129826 DBX1 2.99E-08 0.0167 0.033 0.023 
4 19 rs157582 TOMM40 2.29E-16 1.25E-10 0.068 0.001 16 21 rs11910985 S100B 3.17E-08 0.0177 0.033 0.023 
5 1 rs13376197 B3GALT2 3.04E-10 0.00017 0.042 0.031 17 21 rs1981331 S100B 3.19E-08 0.0178 0.033 0.023 
6 12 rs3020811 LRP6 1.24E-08 0.0069 0.030 0.026 18 3 rs9872004 AADACL1 3.26E-08 0.0181 0.033 0.023 
7 9 rs2280302 FBP1 1.28E-08 0.0071 0.035 0.026 19 1 rs17027633 ATP5F1 3.26E-08 0.0182 0.033 0.023 
8 9 rs2280301 FBP1 1.37E-08 0.0076 0.035 0.026 20 1 rs6662771 SGIP1 3.44E-08 0.0192 0.033 0.023 
9 10 rs12265790 ITGA8 1.85E-08 0.0103 0.034 0.024 21 11 rs12797204 DLG2 3.71E-08 0.0206 0.033 0.025 
10 10 rs7896076 ITGA8 1.87E-08 0.0104 0.034 0.024 22 18 rs6506440 ARHGAP28 7.51E-08 0.0414 0.032 0.026 
11 10 rs11253637 ITGA8 1.91E-08 0.0107 0.034 0.024 23 2 rs6541929 CNTNAP5 7.64E-08 0.0421 0.032 0.027 
12 1 rs1539581 ATP5F1 2.34E-08 0.0130 0.034 0.024 24 2 rs17267326 CNTNAP5 8.23E-08 0.0453 0.031 0.028 
 a Model: Percent of additional variance in T-tau/Aß42 level explained by the main effect of SNPs after accounting for age, gender, and diagnosis. 
 b Model: Percent of additional variance in T-tau/Aß42 level explained by the main effect of SNPs after accounting for age, gender, diagnosis, and the APOE 
genotype. 
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and the APOE e4 status. The main effects of rs4420638, 
rs769449, rs2075650, and rs157582 account for 10%, 9.1%, 
7.1%, and 6.8% of phenotypic variance respectively while 
controlling for age, gender and diagnosis, but account for 
≤0.1% variance after removing the APOE e4 status. The most 
significant AD-risk factor APOE e4 SNP (rs429358) accounts 
for 12.9% variance (Table 3). The total amount of additional 
variance explained by 24 identified SNPs is 11.3% after 
accounting for age, gender, diagnosis and APOE e4 status, and 
up to 41.6% while including all factors (age, gender, diagnosis, 
APOE and 24 SNPs). 
3.2. Genome-wide interaction study results 
 Our two-marker interaction model considered age, gender, 
and clinical diagnosis as covariates. 307 pairs of SNPs showed 
statistically significant interaction effects on the T-tau/Aß42 
level (Bonferroni-corrected p-value<0.05). Only 7 pairs passed 
the cell-size criterion: all the cell sizes in 3-by-3 contingency 
table are required to be either more than 5 or equal to 0. The 
results of two-marker interaction were: rs1514061 (PLXNA4*) 
- rs6467419 (PLXNA4*), rs1514061 (PLXNA4*) - rs4453471 
(CDH13), rs7303599 (ADIPOR2*) - rs7146454 (ADSSL1*), 
rs7303599 (ADIPOR2*) - rs167396 (GSN*), rs1482548 
(INHBA*) - rs12894119 (NIN*), rs9550406 (MTUS2*) - 
rs6471951 (RLBP1L1), rs211953 (CXADR) - rs4881147 
(PITRM1*), where * indicating nearest gene proximal to the 
SNP. Details are available in Table 3. 
3.3. Post hoc analysis 
 Table 3 also shows the two-marker interaction results of post 
hoc analysis on T-tau/Aß42 level. Age, gender, and diagnosis 
were first included in the model and accounted for 17.4% of 
variance on the T-tau/ ß42 level. APOE status was then 
accounted for an additional 12.9% of variance. For each 
interaction, we ran a hierarchical linear regression model. We 
first added in the genetic main effects, and then the genetic 
interaction term to determine the variance associated with the 
interaction term alone. For rs1514061 (PLXNA4*) - rs6467419 
(PLXNA4*), the SNPs’ main effects accounted for 1.5% of 
variance, and the interaction term accounted for 5.1% of 
variance (6.6% combined). For rs1514061 (PLXNA4*) - 
rs4453471 (CDH13), the main effects accounted for 1.9% of 
variance, and the interaction accounted for 4.7% of variance 
(6.6% combined). For rs7303599 (ADIPOR2*) - rs7146454 
(ADSSL1*), the main effects accounted for 2.3% of variance, 
and the interaction term accounted for 4.2% of variance (6.5% 
combined). For rs7303599 (ADIPOR2*) - rs167396 (GSN*), 
the main effects accounted for 2.1% of variance, and the 
interaction term accounted for 4.1% of variance (6.2% 
combined). For rs1482548 (INHBA*) - rs12894119 (NIN*), the 
main effects accounted for 1.5% of variance, and the interaction 
term accounted for 3.8% of variance (5.3% combined). For 
rs9550406 (MTUS2*) - rs6471951 (RLBP1L1), the main 
effects accounted for 1.0% of variance, and the interaction 
accounted for 3.4% of variance (4.4% combined). For rs211953 
(CXADR) - rs4881147 (PITRM1*), the main effects accounted 
for 2.4% of variance, and the interaction term accounted for 
3.1% of variance (5.5% combined).  
4. Discussion 
 In this work, we performed GWAS and GWIS of the CSF 
biomarker T-tau/Aß42 ratio, using a sample of 843 subjects   
from the ADNI database. To our knowledge, this genome-wide 
study on detecting two-marker interaction is the first GWIS on 
the quantitative trait of the T-tau/Aß42 level. 
 In single-marker analysis, we identified the SNPs in APOE, 
APOC1 and TOMM40 genes (Fig. 2), which showed high-level 
genome-wide significant associations to the T-tau/Aß42 ratio. 
We also revealed 20 additional significant loci, within or 
proximal to LRP6, S100B, DLG2, CNTNAP5, B3GALT2, 
FBP1, ITGA8, ATP5F1, LPAR3, DAPK2, DBX1, AADACL1, 
SGIP1, and ARHGAP28 genes (Table 2). The previously 
reported AD risk genes APOE, APOC1, and TOMM40 were 
replicated in our GWAS (Supplementary Table s4). In addition, 
the S100B, CNTNAP5, LRP6, and DLG2 genes were also 
reported to have pathological relevances in AD. S100B shows a 
pathological relevance for degeneration of the central nervous 
system in AD (Petzold et al.,2003), and overexpression of 
S100B in the neuritic plaques of AD is related to the degree of 
neuritic pathology in Aß plaques (Peskind et al., 2001). 
CNTNAP5 encodes the protein belonging to the neurexin 
family functioning in the central nervous system as cell 
 
Fig. 2.  Manhattan plot of the observed -log10(p-values) from the GWAS CSF. More than 560,000 SNPs were tested for association to T-tau/Aβ42 level under an 
genotypic model with age, gender and diagnosis as covariates. Genome-wide associations identified 22 significant SNPs (Bonferroni-corrected threshold is 
p-value < 0.05 and represented by the red line), and the top 4 significant SNPs were on chromosome 19 within the APOE and its neighboring regions. 
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adhesion molecules and receptors, and has been implicated as a 
risk factor for posterior cortical atrophy variant of AD (Schott 
et al., 2016). Neuronal LRP6 mediated Wnt signaling has an 
impact on synaptic function and cognition, and genetic variants 
in the LRP6 gene have been linked to AD risk (Liu et al., 2014). 
A proteomics study showed AD-dependent changes in  the 
DLG2 level in the hippocampus, and DLG2 exhibits an 
early-up, late-down expression pattern during AD pathology 
(Hondius et al., 2016). Our exploratory GWAS nominates the 
others novel loci, such as B3GALT2, FBP1, ITGA8, ATP5F1, 
LPAR3, DAPK2, DBX1, AADACL1, SGIP1 and ARHGAP28, 
meeting the genome-wide significance. These potential 
T-tau/Aß42 related quantitative trait loci (QTLs) warrant further 
investigation. 
    SNP-SNP interaction studies may explain part of the 
“missing heritability”. The recent studies (Shen et al., 2014) in 
ADNI cohort demonstrated “case-control” studies for testing 
epistasis interaction. In this study, we preformed two-marker 
interaction analyses using the T-tau/Aß42 ratio as quantitative 
trait for increasing statistical power and reducing required 
sample sizes. Our method revealed 7 pairs of SNPs within or 
proximal to 11 genes meeting the criterion of the cell size either 
more than 5 or equal to 0 and a Bonferroni corrected threshold 
(corrected p-value ≤ 0.05). As we expected, the significant 
variants in these pairs all have marginal dominance effects, but 
their interactions can explain a relatively high-level variances 
of the T-tau/Aß42 ratio (Table 3), and high-level AD risk. The 
bar charts of the QT measures across SNP-by-SNP genotype 
combinations are shown in Fig. 3.  
 In previous studies, PLXNA4 has been reported to be 
associated with precise positioning of OPCs (oligodendrocyte 
precursor cells) in developing cerebral cortex. Then it has also 
suggested that PLXNA4 does not influence APP processing or 
Aβ production but its isoform differentially affects tau protein 
phosphorylation (Jun et al., 2014) involved in AD 
pathogenesis, leading to neurofibrillary tangle formation and 
neuronal death (Wang et al., 2016). CDH13 gene has been 
linked to brain function or neuropsychiatric disorders, affecting 
morphometry of the temporal lobes (a typical AD biomarker) 
(Kohannim et al., 2012). With these observations, the identified 
PLXNA4-PLXNA4 and PLXNA4-CDH13 interactions may have 
a potential on contributing to the tau pathway instead of Aβ.  
 ADIPOR2 (Adiponectin Receptor 2) is a protein coding 
gene, and adiponectin is the most abundant adipokine secreted 
from adipose tissue. Globular adiponectin has been reported to 
induce a pro-inflammatory response in human astrocytic cells 
(Chan et al., 2012; Wan et al., 2014). Aβ caused 
neuroinflammation plays a critical role in the development of 
neurodegenerative disorder in AD pathogenesis. ADSSL1 is an 
Aβ toxicity modifier gene, and also an intracellular protein 
responsible for catalyzing the first step of de novo biosynthesis 
of AMP. Its genetic variation has been shown to affect AD 
neuropathology and episodic memory (Rosenthal et al., 2012). 
GSN (Gelsolin) is a protein coding gene, and Gelsolin is one of 
the most abundant actin-binding proteins. Gelsolin binds to Aβ 
protein, inhibits its fibrillization, solubilizes preformed Aβ 
fibrils, and helps in its clearance from the brain (Yang et al., 
2014). It is involved in several pathological processes, 
including AD (Deng et al., 2015). With these observations, the 
identified ADIPOR2-ADSSL1 and ADIPOR2-GSN interactions 
could be related to the Aβ pathway. 
Table 3. Seven significant SNP-SNP interaction pairs identified in the GWIS of the T-tau/Aß42 ratio. 
NO. SNP1×SNP2 GENE CHR 
Main Effect   Interaction   Explained Variance (R Square) 
p-value  p-value Corrected p-value  Age+Gender
a
 Dxb APOEc SNP1+SNP2d SNP1*SNP2e 
1 
rs1514061× PLXNA4* 7 3.41E-06 
8.35E-10 0.0181 0.01 0.164 0.129 0.015 0.051 
rs6467419 PLXNA4* 7 0.00167353 
2 
rs1514061× PLXNA4* 7 3.41E-06 
1.97E-10 0.0043 0.01 0.164 0.129 0.019 0.047 
rs4453471 CDH13 16 0.00377003 
3 × 
rs7303599× ADIPOR2* 12 7.91E-05 
 
5.76E-11 0.0013 0.01 0.164 0.129 0.023 0.042 
rs7146454 ADSSL1* 14 0.00733134 
 
4 
× 
rs7303599× ADIPOR2* 12 7.91E-05 
 
6.91E-10 0.0150 0.01 0.164 0.129 0.021 0.041 
rs167396 GSN* 9 0.00583631 
5 
rs1482548× INHBA* 7 0.007007 
2.95E-10 0.0064 0.01 0.164 0.129 0.015 0.038 
rs12894119 NIN* 14 0.00867969 
6 
rs9550406× MTUS2* 13 0.00543688 
1.49E-09 0.0324 0.01 0.164 0.129 0.010 0.034 
rs6471951 RLBP1L1 8 0.00604041 
7 
rs211953× CXADR 21 0.000478713 
3.03E-10 0.0066 0.01 0.164 0.129 0.024 0.031 
rs4881147 PITRM1* 10 0.0015086 
The Bonferroni corrected p-values (< 0.05) and R2of the SNP*SNP interaction term are shown in bold. 
a Age+Gender: Percent of variance in T-tau/Aß42 level explained by age, gender. 
b
 Dx: Percent of variance in T-tau/Aß42 level explained by diagnosis after accounting for age, gender. 
c APOE: Percent of additional variance in T-tau/Aß42 level explained by the APOE genotype after accounting for age, gender and diagnosis. 
d SNP1+SNP2: Percent of additional variance in T-tau/Aß42 level explained by the combined main effect of SNP1 and SNP2 after accounting for age, 
gender, diagnosis, and the APOE genotype. 
e SNP1*SNP2: Percent of additional variance in T-tau/Aß42 level explained by the interaction effect of SNP1 and SNP2 after accounting for age, 
gender, diagnosis, APOE genotype, SNP1 and SNP2. 
* Nearest gene proximal to the SNP. 
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 The protein encoded by the INHBA gene has been linked to 
neuroprotection via preventing neurons from mitochondrial 
dysfunction, a major cause of excitotoxicity. The 
corresponding process, providing protection against ischemic 
brain damage, could be altered in AD, or aging-related 
neurodegenerative conditions (Lau et al., 2015). The NIN gene 
encodes ninein (GSK3B interacting protein), and variants of 
GSK3B have been shown to be linked with AD and interacted 
with the APOE genotype (Izzo et al., 2013). The MTUS2 gene 
encodes microtubule associated tumor suppressor candidate 2, 
also known as cardiac zipper protein or CAZIP. CAZIP has 
been shown to play a role in the development and function of 
the heart and nervous system in vertebrates (Du Puy et al., 
2009). PITRM1 is responsible for significant Aβ degradation, 
and the impairment of its activity results in Aβ accumulation 
(Brunetti et al., 2016). The possible mechanisms behind 
INHBA-NIN, MTUS2-RLBP1L1, and CXADR-PITRM 
interactions warrant further investigation.  
 In summary, some of the genes identified in our GWAS and 
GWIS have shown interesting associations with tauopathies 
and/or amyloid pathology related to AD from prior knowledge 
of current literatures, such as APOE, APOC1, TOMM40，?
LRP6, S100B, DLG2, CNTNAP5, PLXNA4, CDH13, 
ADIPOR2, ADSSL1, GSN, and PITRM genes (see 
Supplementary Tables s4a and s4b). Supplementary Tables s4a 
and s4b showed that these 13 genes were reported in previous 
genomic, cell culture, mouse model and biomarker studies, and 
shown to be significantly associated to CSF Aß42, CSF T-tau 
or other AD endo-phenotypes. However, in this work, only 
APOE, APOC1, TOMM40 genes showed significant 
associations to the CSF Aß42, T-tau and T-tau/ Aß42 levels, 
other genes were not identified by GWAS and GWIS of Aß42 
alone or T-tau alone (Supplementary Table s2 and Table s3). 
This indicates that, when CSF Aß42 alone and T-tau alone show 
less power for detecting the risk variants, the T-tau/ Aß42 ratio 
has the potential to serve as a more powerful quantitative trait to 
identify significant variants. In addition, our study also 
revealed numerous SNPs and SNP-SNP pairs that had not yet 
been associated with AD pathology, which warrant further 
investigation or replication in future studies.  
5. Conclusions 
 Aimed at studying a major AD biomarker as phenotype, we 
performed GWAS and GWIS to detect the main genetic effects 
as well as SNP-SNP interaction effects on the CSF T-tau/Aß42 
ratio. The single-marker analysis replicated the APOE, APOC1 
and TOMM40 genes, which are previously confirmed AD risk 
genes. We also identified 14 additional loci within or proximate 
to LRP6, S100B, DLG2, CNTNAP5, B3GALT2, FBP1, ITGA8, 
ATP5F1, LPAR3, DAPK2, DBX1, AADACL1, SGIP1, and 
ARHGAP28. The two-marker interaction analysis identified a 
number of novel interaction findings, which showed strong 
associations with the T-tau/Aß42 ratio. These were interactions 
between PLXNA4 and PLXNA4, between PLXNA4 and 
CDH13, between ADIPOR2 and ADSSL1, between ADIPOR2 
and GSN, between INHBA and NIN, between MTUS2 and 
RLBP1L1, and between CXADR and PITRM1. The effects of 
SNP-SNP interactions showed high-level statistical 
significance, while the corresponding single-marker effects 
were marginal. SNP-SNP interaction effects may help address 
part of “miss heritability”.  
 Our genome-wide association study and interaction study 
have the following strengths. (1) Continuous quantitative trait 
Fig. 3. Seven SNP pairs with significant genome-wide interaction effects on the 
T-tau/Aβ42 ratio: The mean T-tau/Aβ42 ratio is plotted against each pairwise genotype 
combination and the error bar indicates the standard deviation. 
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T-tau/Aß42 can not only gain higher statistical power, but also 
contribute to detecting potential risk variants related to T-tau 
and/or Aß42 at the same time. (2) Five values (1-5) indicating 
CN, SMC, EMCI, LMCI and AD respectively, provide a rank 
ordered spectrum of the AD progression. (3) In this study, both 
GWAS and GWIS consider age, gender, and clinical diagnosis 
as covariates. In the post hoc linear regression analysis we 
included confounding factors APOE ε4 allele (rs429358) on top 
of the above three covariates, and so provided more accurate 
estimate of the interaction effects on CSF T-tau/Aß42 ratio.  
The limitations of our study are as follows: (1) We examined 
22 million SNP-SNP pairs and conducted an exhaust test 
among the SNPs. More effective and efficient strategies remain 
to be developed. (2) To control for potential false positives of 
the GWIS findings, we used two methods. One is the 
Bonferroni method, which corrects for multiple comparison by 
using a threshold of α/n and is well-known to be a conservative 
approach. Another method used in the work is the cell-size 
criterion, which excludes rare genotype combinations to avoid 
potential false positives. In this work, we set α=0.05 and n= 
21,717,345 for Bonferroni correction; and for the cell-size 
criterion, all the cell sizes in the 3-by-3 contingency table are 
required to be either more than 5 or equal to 0. There are 307 
pairs SNPs passed the first threshold, and subsequently only 7 
pairs among 307 pairs passed the second threshold for further 
study. Although these are relatively stringent criteria for 
controlling false positives, future replication studies are 
required to confirm the identified interaction signals. (3) We 
performed the GWAS and GWIS of CSF T-tau/Aß42 ratio using 
data-driven method. Future studies could utilize prior 
biological knowledge, such as biological networks, pathways 
databases, special tissues and other functional annotation data, 
to enhance statistical power and improve biological 
interpretability. (4) Future studies are necessary to replicate and 
validate the findings in independent datasets, and to uncover 
potential mechanisms underlying tagged by the identified SNPs 
and genes in our study.  
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Highlights 
 
• SNP-SNP interaction effects may help address part of “miss heritability”. 
• GWAS and GWIS of T-tau/Aß42 ratio were performed on the landmark ADNI database.  
• This is the first GWIS on the quantitative trait of the T-tau/Aß42 ratio. 
• The interaction results had marginal main effects but explained relatively high level T-tau/Aß42 
variance. 
